Document:

EX-10.18.7

 Exhibit 10.18.7 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS
WARRANT IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE HOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

BIOCEPT, INC. 
 WARRANT TO PURCHASE PREFERRED STOCK 
  

			
	No. PSW-    	  	                    , 2011

  

THIS CERTIFIES THAT, for value received,
[INSERT PURCHASER], or its assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from BIOCEPT,
INC., a California corporation (the “Company”), up to such number and series of fully paid and nonassessable shares of Preferred Stock of the Company as set forth herein, during the Exercise
Period (as defined below). 
 This Warrant is issued pursuant to the Note and Warrant Purchase Agreement, dated
February 1, 2011, as amended, among the Company and the Holder (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company also issued Holder a Secured Convertible Promissory Note of even date herewith
(the “Note”) in the principal amount of $[INSERT AMOUNT]. Capitalized terms used and not otherwise defined herein shall have the meanings given to them in the Purchase Agreement. 

1.       DEFINITIONS.    As
used herein, the following terms shall have the following respective meanings: 

(a)     “Exercise Period” shall mean the period commencing on the
date hereof and ending five (5) years thereafter, unless sooner terminated as provided below. 

(b)     “Exercise Price” shall mean (a) if no portion of the
Note has been converted, $0.54 and (b) if all or any portion of the Note has been converted, the price per share at which the Note was first converted into securities of the Company. 

(c)     “Exercise Shares” shall mean (a) the equity securities
of the Company into which the Note is converted upon the automatic or optional conversion of the Note as 

 
provided for in the Note or (b) if the Note has not converted upon the automatic or optional conversion of the Note as provided for in the Note, the Company’s Series BB Preferred Stock.

 (d)     “Warrant Coverage Amount” shall mean the
principal amount of the Note, multiplied by .20. 
 2.      
NUMBER OF SHARES.    The number of Exercise Shares for up to which this Warrant may be exercisable shall be determined by dividing the Warrant Coverage Amount by the Exercise
Price, and rounding down to the nearest whole share. 
 3.      
EXERCISE OF WARRANT.    The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the
Company at its address set forth on the signature page hereto (or at such other address as it may designate by notice in writing to the Holder): 
 (a)     An executed Notice of Exercise in the form attached hereto; 
 (b)     Payment of the Exercise Price either (i) in cash or by check, (ii) by cancellation of indebtedness, or (iii) any combination thereof; and 

(c)     This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so
purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so
exercised. 
 The person in whose name any certificate or certificates for Exercise Shares are to be issued upon
exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or
certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next
succeeding date on which the stock transfer books are open. 
 4.      
COVENANTS OF THE COMPANY. 

4.1     Covenants as to Exercise Shares.    The Company covenants and
agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with
respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares to provide for the
exercise of the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares is not sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in
the opinion of its counsel, be necessary to increase its authorized but unissued shares to such number of shares as shall be sufficient for such purposes. 

  
 2. 

 4.2     No Impairment. Except and to the extent
as waived or consented to by the Holder, the Company will not, by amendment of its Amended and Restated Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this
Warrant and in the taking of all such action as may be necessary or appropriate in order to protect the exercise rights of the Holder against impairment. 
 5.       ADJUSTMENT OF EXERCISE PRICE.  In the event of changes in the outstanding Preferred
Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under the
Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had
the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall
terminate if not exercised prior to, the events set forth in Section 8 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

6.       ADJUSTMENTS FOR DILUTING
ISSUANCES.  The Exercise Price and the number of Exercise Shares issuable upon exercise of this Warrant or, if the Exercise Shares are Preferred Stock, the number of shares of common stock issuable upon conversion of the
Exercise Shares, shall be subject to adjustment, from time to time in the manner set forth in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time, as if the Exercise Shares were issued and outstanding on
and as of the date of any such required adjustment. Any adjustment to the conversion rate of the Exercise Shares issuable upon the exercise of this Warrant effected prior to any exercise of this Warrant shall apply to any Exercise Shares thereafter
issued pursuant to the terms hereof. 
 7.       FRACTIONAL
SHARES.  No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be
aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any
fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

8.       EARLY TERMINATION.  In the event
of, at any time during the Exercise Period, an initial public offering of securities of the Company registered under the Securities Act, or any capital reorganization, or any reclassification of the capital stock of the Company (other than a change
in par value or from par value to no par value or no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), or an Asset Transfer or Acquisition (as defined in the Company’s Amended and
Restated Articles of Incorporation, as amended) (other than a merger solely to effect a reincorporation of the Company into another 

  
 3. 

 
state), the Company shall provide to the Holder 20 days advance written notice of such public offering, reorganization, reclassification, consolidation, merger or sale or other disposition of the
Company’s assets, and this Warrant shall terminate unless exercised prior to the date such public offering is closed or the occurrence of such reorganization, reclassification, consolidation, merger or sale or other disposition of the
Company’s assets. 
 9.       MARKET
STAND-OFF AGREEMENT.  Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale with respect to, any Common Stock (or other securities) of the Company held by such Holder, for a period of time specified by the managing underwriter(s) not to exceed 180 days following the effective date of a
registration statement of the Company filed under the Securities Act in connection with the Company’s initial public offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the
Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation). Holder agrees to execute and deliver such other agreements as may be reasonably requested by the
Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
such Common Stock (or other securities) until the end of such period. Each Holder agrees that any transferee of Common Stock (or other securities) shall be bound by this Section 9. The underwriters of the Company’s stock are intended third
party beneficiaries of this Section 9 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 10.       NO SHAREHOLDER RIGHTS.  This Warrant in and of itself shall not entitle the Holder to any voting
rights or other rights as a shareholder of the Company. 
 11.      
TRANSFER OF WARRANT.  Subject to applicable laws and the restrictions on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person
or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company.

 12.       LOST, STOLEN,
MUTILATED OR DESTROYED WARRANT.  If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably
impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original
contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 13.       NOTICES, ETC.  All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

  
 4. 

 
All communications shall be sent to the Company and the Holder at the address set forth on the signature page hereto, or at such other address as the Company or Holder may designate by 10 days
advance written notice to the other party hereto. 
 14.      
ACCEPTANCE.    Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 

15.       COUNTERPARTS.    This Warrant may be
executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 16.       GOVERNING LAW.    This Warrant shall be governed by, and construed and enforced in accordance with, the
laws of the State of California, applied to agreements between California residents, made to be performed entirely within the State of California, without giving effect to conflicts of law principles. 

17.       AMENDMENT;
WAIVER.    Any term of this Warrant may be amended or waived with the written consent of the Company and the Holder. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 5. 

 IN WITNESS
WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of the date set forth above. 

 

			
	BIOCEPT, INC.
		
	By:	 	 

 
			
		
	Name:	 	 

 
			
		
	Title:	 	 
	
	 Address: 5810 Nancy Ridge Drive
                 San Diego, California 92121

  

			
	Acknowledged and accepted:
	
	[INSERT PURCHASER]
		
	By:	 	 

			
		
	Name:	 	 

			
		
	Title:	 	 

			
		
	Address:	 	 
		
		 	 

 [SIGNATURE PAGE TO WARRANT] 

 NOTICE OF EXERCISE 
 TO: BIOCEPT, INC. 

(1)       The undersigned hereby elects to purchase
                 Exercise Shares of Biocept, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any. 

(2)       Please issue a certificate or certificates representing said Exercise
Shares in the name of the undersigned or in such other name as is specified below: 
  

 
 (Name)

  
  

 
  

(Address) 
 (3)       The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for the account of the undersigned for investment and not with a
view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and financial
condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of this type and has such
knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that the
Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the
Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely
unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act
unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company
and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid Exercise Shares unless and until there is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to
the Company, stating that such registration is not required. 
  

					
	  
 (Date)
	 		 	  

(Signature)

			
		 		 	
		 		 	  
 (Print
name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this 
 form and supply required information. Do not use this 
 form to purchase shares.)

 FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to 
  

			
	Name:	  	
		  	(Please Print)
		
	Address:	  	
		  	(Please Print)

 Dated:
                    , 20__ 

Holder’s 
 Signature:
                                         
                    
 Holder’s

 Address:
                                         
                      
 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.19

 Exhibit 10.19 
 BIOCEPT, INC. 
 NOTE AND WARRANT PURCHASE AGREEMENT 

THIS NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of January 13, 2012 (the “Effective Date”) by and among BIOCEPT,
INC., a California corporation (the “Company”) and the Investors listed on the Schedule of Investors attached hereto (each an “Investor” and
collectively, the “Investors”). 
 RECITALS 

WHEREAS, in exchange for a series of loans in an aggregate amount equal to
$1,750,000 from the Investors, the Company will issue promissory notes and warrants to purchase shares of the Company’s Preferred Stock (the “Preferred Stock”) to the Investors. 

AGREEMENT 
 NOW THEREFORE, the parties to this Agreement, for good and valuable consideration, the receipt and sufficiency of which is acknowledged and agreed,
hereby agree as follows: 
 1.        LOAN AMOUNT;
ISSUANCE OF NOTES AND WARRANT. 

1.1        Loan Amount; Issuance of Notes.    Subject
to the terms of this Agreement, the Investors agree, jointly and severally, to lend the Company at each Closing (as defined below), the amount set forth on the Schedule of Investors attached hereto (each, a “Loan Amount” and
collectively the “Loan”) against the issuance and delivery by the Company of promissory notes for such amounts, in substantially the form attached hereto as Exhibit A (each, a “Note” and
collectively, the “Notes”). 

1.2        Issuance of Warrants.    Subject to the
terms of this Agreement, the Investors agree to purchase from the Company, and the Company agrees to issue to the Investor, a Warrant in the form attached hereto as Exhibit B (the “Warrant”) to purchase the number
of shares of Preferred Stock set forth in the Warrant (the “Warrant Shares”). 

2.        CLOSINGS; DELIVERY. 

2.1        Initial Closing.    The initial closing of
the purchase and sale of the Notes (the “Initial Closing”) shall be held on the date hereof at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121, or at such other time and place as the Company and the
Investors mutually agree. 
 (a)        Deliveries by the
Company.    At the Initial Closing, the Company shall deliver (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto under the heading “Initial Closing Principal
Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 

  
 1. 

 (b)        Deliveries by
Investor.    At the Initial Closing, the Investors participating in the Initial Closing shall deliver to the Company funds, by check or wire transfer, in the amount set forth opposite such Investor’s name on the Schedule
of Investors attached hereto under the heading “Initial Closing Principal Amount of Note.” 

2.2        Additional Closings.    If, at any time
prior to the Maturity Date (as defined in the Notes), (i) the Company has less than $1,000,000 of cash and cash equivalents and (ii) the Company has received a term sheet for a Qualifying Financing (as defined in the Notes) that is
acceptable to the Company’s Board of Directors (the requirements set forth in (i) and (ii) are referred to herein as the “Draw-Down Requirements”), then the Chief Executive Officer of the Company shall be
permitted to deliver a written notice (the “Draw-Down Notice”) to the Reiss Family Survivor’s Trust UDT dated December 18, 1988 (the “Major Investor”) and any other potential
investor in the Company approved by the Chief Executive Officer of the Company (any such investor, a “New Investor” and collectively, the “New Investors”), which Draw-Down Notice shall
certify that the Draw-Down Requirements have been satisfied and shall specify the closing of the sale of a specific amount of the authorized Notes and Warrants (such amount in any Draw-Down Notice, the “Draw-Down Amount”) not
previously sold by the Company (each an “Additional Closing” and together with the Initial Closing, a “Closing”), which such Additional Closing shall occur no earlier than two and no later than five
business days after the delivery of the Draw-Down Notice. Notwithstanding the foregoing, the Major Investor shall not be required to participate in an Additional Closing during any calendar month to the extent that the Company has effected two
Additional Closings in such calendar month. Following each Additional Closing, the Schedule of Investors under the heading “Additional Closing Principal Amount of Note” shall be unilaterally updated by the Company to record the names of
Investors participating in such Additional Closing and the principal amount of each Investor’s Loan Amount being made at such Additional Closing. 
 (a)        Deliveries by the Company.    At each Additional Closing, the Company shall deliver (a) to each Investor participating in
such Additional Closing, a duly executed Note (in the principal amount of Investor’s Loan Amount being made at such Additional Closing) and (b) to each Investor participating in such Additional Closing that has not previously been issued a
Warrant pursuant to this Agreement, a duly executed Warrant to purchase the Warrant Shares. 

(b)        Deliveries by Investors.    At each
Additional Closing, (i) the Major Investor shall deliver to the Company funds, by check or wire transfer, in an amount equal to the Draw-Down Amount, less any amounts of the Draw-Down Amount that have been committed to be funded by New
Investors in such Additional Closing, and (ii) the New Investors shall deliver to the Company funds, by check or wire transfer, in an amount equal to their commitment of the Draw-Down Amount in such Additional Closing. 

Each New Investor not a party to this Agreement shall become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement and any Notes and Warrants sold pursuant to this Section 2.2 shall be deemed to be “Notes” and “Warrants” for all purposes under this Agreement and any New Investors
thereof shall be deemed to be an “Investor” for all purposes under this Agreement. 

  
 2. 

 The issuance of the Notes and any Warrants to the Investors at each Closing,
as applicable, shall be made on the terms and conditions set forth in this Agreement, provided that (i) the representations and warranties of the Company set forth in Section 3 hereof shall speak as of the date of such Closing and
(ii) the representations and warranties of each Investor participating in such Closing set forth in Section 4 hereof shall speak as of the date of such Closing. 
 3.        REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 The Company hereby represents and warrants to each Investor, as of each Closing, as applicable, as follows:

 3.1        Organization and Standing; Articles and
Bylaws.    The Company is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of California and is in good standing under such laws. The Company has the requisite corporate power
to own and operate its properties and assets, and to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified and is authorized to transact business and is in good standing as a foreign corporation
in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business, properties, or financial condition. 
 3.2        Corporate Power.    The Company will have at each Closing all requisite legal and corporate power to execute and deliver this
Agreement and to carry out and perform its obligations under the terms of this Agreement. 

3.3        Authorization.    All corporate action on
the part of the Company, its directors and its shareholders necessary for the authorization, execution, delivery and performance of this Agreement, the Notes and the Warrant (collectively, the “Loan Documents”) by the Company
and the performance of the Company’s obligations hereunder and thereunder, including the issuance and delivery of the Notes and Warrant and the reservation of the equity securities issuable upon exercise of the Warrant (collectively, the
“Conversion Shares” and, together with the Notes and the Warrants, the “Securities”) has been taken or will be taken prior to the issuance of such Securities, as applicable. The Loan Documents, when
executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights, (b) as limited by general principles of equity that restrict the availability of equitable remedies and (c) with respect to rights to
indemnity, subject to federal and state securities laws. The Securities, when issued in compliance with the provisions of the Loan Documents, will be validly issued, fully paid and nonassessable. The issuance of the Securities pursuant to the
provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company that will not be validly complied with or waived. The Securities, when issued in compliance with the provisions of the Loan
Documents, will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Investor through no action of the Company; provided, however, that the Securities may be subject to restrictions on
transfer under (i) that certain Amended and Restated Investor Rights Agreement, by and among the Company and the 

  
 3. 

 
other signatories thereto, dated October 31, 2011 (the “Investor Rights Agreement”), (ii) the Company’s Bylaws and (iii) state and/or federal
securities laws. 
 3.4        Governmental
Consents.    All consents, approvals, orders, or authorizations of, or registrations, qualifications, designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection
with the valid execution and delivery of the Loan Documents, the offer, sale or issuance of the Securities, or the consummation of any other transaction contemplated hereby shall have been obtained and will be effective at the Initial Closing and at
each subsequent Closing, except for notices required or permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis. 

3.5        Offering.    Assuming the accuracy of the
representations and warranties of the Investor contained in Section 4 hereof, the offer, issue, and sale of the Notes and the Warrant are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of
1933, as amended (the “Securities Act”), and have been registered or qualified (or are exempt from registration and qualification) under the registration, permit, or qualification requirements of all applicable state
securities laws. 
  

	4.        REPRESENTATIONS 	AND WARRANTIES OF THE INVESTOR. 

Each Investor hereby represents and warrants to the Company as of each Closing in which such Investor participates, as
applicable, as follows: 
 4.1        Requisite Power and
Authority.    The Investor has all necessary power and authority to execute and deliver this Agreement and the Loan Documents and to carry out their provisions. All action on the Investor’s part required for the lawful
execution and delivery of this Agreement and the Loan Documents has been taken. Upon their execution and delivery, this Agreement and the Loan Documents will be valid and binding obligations of the Investor, enforceable against the Investor in
accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general
principles of equity that restrict the availability of equitable remedies. 

4.2        Purchase for Own Account.    The Investor
represents that it is acquiring the Securities solely for its own account and beneficial interest for investment only, and not for sale or with a view to distribution of the Securities or any part thereof, has no present intention of selling (in
connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention. 

4.3        Information and Sophistication.    The
Investor (i) acknowledges that it has received all the information that it or its qualified purchaser representative has requested from the Company and that it considers necessary or appropriate for deciding whether to acquire the Securities,
(ii) represents that it or its qualified purchaser representative has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain any additional
information necessary to verify the 

  
 4. 

 
accuracy of the information given the Investor and (iii) further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the
merits and risk of this investment. Without limiting the foregoing, the Investor is relying on its own independent investigation of the Company and on its own respective professional advisors in entering into this Agreement and consummating the
transactions described herein. 
 4.4        Ability to Bear Economic
Risk.    The Investor acknowledges that investment in the Securities involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Securities for an
indefinite period of time and to suffer a complete loss of its investment. 

4.5        Further Limitations on
Disposition.    Without in any way limiting the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Securities unless and until: 

(a)        There is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (b)        (i) The transferee has agreed in writing to be bound by the terms of this Agreement, (ii) the Investor shall have notified the Company of the
proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (iii) if reasonably requested by the Company, the Investor shall have furnished the Company with
an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made
pursuant to Rule 144, except in unusual circumstances. The Company will not require the transferee to be bound by the terms of this Agreement after the Company’s first firm commitment underwritten public offering of its Common Stock registered
under the Securities Act (the “Initial Offering”). 

(c)        Notwithstanding the provisions of subsections (a) and
(b) above, no such restriction shall apply to a transfer by the Investor to an entity affiliated by common control (or other related entity) with the Investor (each such transferee, an “Affiliate” of the
Investor); provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Investor hereunder. 

(d)        Each certificate evidencing the Securities to be issued to the
Investor shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under (i) the Investor Rights Agreement, (ii) the Company’s Bylaws and (iii) applicable
state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL

  
 5. 

 
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE
INVESTOR AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (e)        The Company shall be obligated to reissue promptly unlegended certificates representing any Securities held by the Investor at the request of the
Investor if the Company has completed its Initial Offering and the Investor has obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be
disposed of may lawfully be disposed of without registration, qualification and legend. 

(f)        Any legend endorsed on an instrument pursuant to applicable
state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate state securities authority authorizing such removal. 

4.6     Accredited Investor Status.    The Investor is an accredited
investor or is represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 

5.     FURTHER ASSURANCES.    The
Company and each Investor agree and covenant that at any time and from time to time it will promptly execute and deliver to each other such further instruments and documents and take such further action as each of the parties hereto may reasonably
require in order to carry out the full intent and purpose of this Agreement. 
  

	6.	MISCELLANEOUS. 

 6.1        Binding Agreement.    The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 
 6.2        Governing
Law.    This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California
without giving effect to its conflicts of laws principles. 

  
 6. 

 6.3        Counterparts;
Facsimile.    This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as
original signatures. 

6.4        Expenses.    Each party shall pay all costs
and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement and the transactions contemplated hereby. 
 6.5        Titles and Subtitles.    The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 

6.6        Notices.    All notices required or
permitted hereunder or under the Notes or the Warrant shall be in writing (including facsimile, electronic mail or similar electronic transmissions), and shall be deemed effectively given: (a) when received by the addressee, if delivered by
hand, facsimile, electronic mail or similar form of electronic transmission, (b) five days after mailing, if mailed by registered or certified mail, return receipt requested, postage prepaid or (c) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent (i) to the Company at 5810 Nancy Ridge Drive, San Diego, California 92121, Attn: Bill Kachioff, or (ii) to
the Investors at the address shown on the Schedule of Investors, or at such other address as such party may designate by written notice to the other party. 
 6.7        Amendment; Waiver.    Except as otherwise set forth herein, no amendment or waiver of any provision of this Agreement shall be
effective unless in writing and approved by (i) the Company and (ii) the holders of at least a majority of the then-outstanding principal amount of all Notes. 

6.8        Expenses.    Each party shall pay all costs
and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. 
 6.9        Delays or Omissions.    It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party,
upon any breach, default or noncompliance by another party under this Agreement, the Notes or the Warrant, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any
acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or
noncompliance under this Agreement, the Notes or the Warrant, or any waiver on such party’s part of any provisions or conditions of this Agreement, the Notes or the Warrant must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies under this Agreement, the Notes or the Warrant, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

6.10        Entire Agreement.    This Agreement and
the exhibits hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and
agreements except as specifically set forth herein. 

  
 7. 

 6.11        California Corporate
Securities Law.    THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT
OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS
AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 8. 

 IN WITNESS
WHEREOF, the parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above.

 COMPANY: 

BIOCEPT, INC., 
 a California corporation 
  

			
		
	By:	 	 
		 	David Hale
		 	Executive Chairman

  
  
  

 
  
 [SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	 THE REISS FAMILY SURVIVOR’S
TRUST
 UDT DATED DECEMBER 19, 1988:

		
	By: 	 	 

 
			
		
	Name: 	 	 

 
			
		
	Title: 	 	 

  
  
  

 
  
  

[SIGNATURE PAGE TO NOTE AND WARRANT
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
		
	By: 	 	 

 
			
		
	  Name: 	 	 

 
			
		
	  Title: 	 	 

  
  
  

 
  
 [SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT] 

 SCHEDULE OF INVESTORS 

 

					
	INVESTOR NAME	  	
INITIAL CLOSING PRINCIPAL

AMOUNT OF NOTE
	  	ADDITIONAL CLOSING
PRINCIPAL AMOUNT OF 
NOTE1
	The Reiss Family Survivor’s Trust UDT dated December 19, 1988	  	$750,000	  	
			
	 Address:
 9675 La Jolla Farms
Road
 La Jolla, CA 92037
	  		  	
			
	[To be determined]	  	$0	  	
			
	 Address:

[_________]
 [_________]
	  		  	
		  	  

	TOTAL:	  	$750,000	  	

  
  
  

 
  
 1 Column to
be updated unilaterally by Company following each Additional Closing. 

 EXHIBIT A 

FORM OF PROMISSORY NOTE 

 EXHIBIT B 

FORM OF WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]